Latest News

Novo Nordisk joins Evotec as drug discovery partner

Hamburg headquarters of Evotec AG. © Evotec


by tg

Novo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets.

The companies announced that they will also seek to find drug candidates to treat co-morbidities such as diabetic kidney disease, nonalcoholic steatohepatitis and cardiovascular diseases. Under the agreement, Evotec will apply its small molecule  drug discovery platform, especially in ligand-based design, to find promising drug candidates to treat patients with diabetes and obesity. Once suitable preclinical candidates are selected, Novo Nordisk will use Evotec’s INDiGO platform – a tech portfolio to assess ADMET acquired for €62m in 2016 by the acquisition of Cyprotec – to move through pre-clinical studies to enter IND registration.

No financial details of the deal were disclosed. However, usual conditions of similar Evotec deals included €1m-10m R&D grants, €150m in milestones per compound and 8% tiered royalties on average. The deal adds new projects to Evotec's portfolio of more than 60 R&D co-owned projects.

Novo Nordisk is a leader in diabetes medicines.The chronic incapacitating disease, which affected about 425 million people worldwide in 2017 (2015: 415 million) and a market of US$727bn, is associated with chronic co-morbidities such as cardiovascular diseases, kidney diseases, nerve damage and eye diseases. Obesity affects more than 650 million adults worldwide and is often cited as a major risk factor for many diseases such as cardiovascular diseases, diabetes, musculoskeletal disorders, and several cancers. Treatment cost in 2017 were estimated over US$800bn in 2017 and is rising steeply.

Abivax SA raises €130m to advance obefazimod to Phase III

Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point...

New polymer can stop biofilm formation

The acrylate co-polymer reported by Jean-Frédéric Dubern and colleagues in Science Advances (doi: 10.1126/sciadv.add7474) have the potential to...

Hummingbird and Synaffix in $150m ADC deal

Under the deal, Synaffix can earn up to $150m, including upfront and milestone payments, plus royalties on net sales if the ADC resulting from the...

Pfizer-Seagen: Acquisition in the works

As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Chong Kun Dang Pharm licences Synaffix ADC platform

Though the companies did not give any financial details, former licencing deals of Synaffix to global pharma companies such as Amgen or ranged...

Roche withdraws checkpoint blocker from the market

Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

Oculis lists at Nasdaq through SPAC merger

Upon closing of the $104m SPAC deal with European Biotech Acquisition Corp, Oculis had a pro-forma enterprise value of approximately $220m and a cash...